BeStock  
Stocks › Biotechnology › GHRS

GH Research GHRS

US equityMarket cap rank #3039Biotechnology
$17.53 −$1.03 (-5.55%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $17.53 0.00%
Open$18.32
Prev close$18.56
Day range$17.29 – $18.32
Volume299.5K
Market cap$1.20B
P/E (TTM)–
Dividend yield–
Founded2021
CEODr. Velichka Valcheva, M.D.,M.Sc.
Employees73
HeadquartersDublin, Ireland
Websitewww.ghres.com

Revenue per employee

73 employees as of 2025/FY (+46.0% YoY). Revenue per employee is total revenue divided by headcount — a rough productivity gauge, not a per-worker pay figure.

Management team

Magnus Halle Managing Director, Ireland
Age 29 · As of 4 Mar 2026
Background

Magnus Halle, has served as our Managing Director, Ireland since November 2020, is one of our co-founders, and served as a consultant to us from our founding in 2018 to 2020. Previously, Mr. Halle served as Analyst at NB Capital ApS, a position he held from 2018 to 2021. Additionally, from 2019, he served as the Money Laundering Reporting Officer at NB Capital ApS. Prior to that, from 2016 to 2018, he was the Personal Assistant to Florian Schonharting at NB Capital ApS. Mr. Halle holds a BSc in Economics and Business Administration from Copenhagen Business School.

Aaron Cameron Chief Operating Officer
Age 41 · As of 4 Mar 2026
Background

Aaron Cameron, has served as our Chief Operating Officer since January 2024. Prior to this, he served as our Vice President, Technical Development since August 2021, before taking the role of Vice President, Technical Development and Operational Planning in December 2022. Previously Mr. Cameron has served in a number of senior technical, supply chain and program management positions including Viatris, where he was Head of Device Program Management from 2020 to 2021, and Iterum Therapeutics, where he held roles as VP, Supply Chain and Logistics and Director of Drug Product Development and Manufacturing, between 2016 and 2021. From 2013 to 2016, Mr. Cameron served in a variety of roles in R&D in Mylan, after serving in a variety of roles in R&D, Commercialization and Manufacturing in MSD between 2006 and 2012. Mr. Cameron holds a B.Sc. in Chemical and Pharmaceutical Sciences from Dublin City University, a M.Sc. in Industrial Pharmaceutical Science from the Royal College of Surgeons, Dublin, and an MBA from Bradford University.

Dermot Hanley Independent Director
Age 61 · As of 4 Mar 2026
Background

Dermot Hanley, has served as a member of our Board of Directors since September 2021. Mr. Hanley is an experienced independent non-executive director and investment banker. He is currently a non-executive board member of numerous private equity backed companies and regulated financial investment funds. These include several group companies of Killiney Maritime II since September 2018 and January 2023, respectively, Larix Opportunities Master ICAV since February 2020 and Varagon Capital Credit Strategies ICAV since October 2020. Additionally, he serves as Chairperson of RTW Royalty ICAV (previously RTW Investment ICAV) since January 2021, 4010 Royalty Investments ICAV and 4010 Investments Fund GP LLC since May 2023, BFO Apogem GP Limited since May 2024, Arcano Direct Lending ICAV I since November 2025, Arcano Direct Lending ICAV II since February 2026, and Chesapeake ICAV IV since February 2026. He founded Nusli in 2012. Previously, Mr. Hanley was Co-Head of Coverage for Barclays Bank Ireland and spent 16 years in international investment banking and capital markets roles with major global firms, including Claret Capital, JP Morgan, Deutsche Bank and Citibank. He is a member of the Governance Advisory Council for The Corporate Governance Institute and was previously a longstanding member of the Finance and Economics Committee (Ecotax) at The Irish Business and Employers Confederation. He is a graduate of University College Dublin (BSc) and The Queen's University of Belfast (MBA) and holds a diploma in corporate governance from The Corporate Governance Institute/Glasgow Caledonia University.

Michael Forer Vice Chairman of the Board
Age 60 · As of 4 Mar 2026
Background

Michael Forer, has served as the Vice Chairman of our Board of Directors since March 2022 and as a member of our Board of Directors since December 2020. Mr. Forer was a co-founder of ADC Therapeutics SA in 2011 and has served as its initial Chief Executive Officer from 2011 to 2015, its Vice Chairman from 2015 to 2023, its Chief Financial Officer through its IPO on the NYSE from 2015 to 2020, its Executive Vice President from 2015 to 2022 and General Counsel from 2020 to 2022. Previously, Mr. Forer was a board member and Executive Director of Spirogen Sarl from 2008 to 2013, leading up to its acquisition by AstraZeneca in 2013 for $440 million. Mr. Forer has extensive experience as a professional investor in the biotech sector, including leading investments in Spirogen and ADC Therapeutics for Auven Therapeutics Holdings L.P. from 2008 to 2015, as a co-founder and partner in Rosetta Capital Limited from 2001 to present, and as an investment manager at Rothschild Asset Management from 1998 to 2001. Mr. Forer holds a B.A. in Economics from the University of Western Ontario and an LL.B. from the University of British Columbia.

Dr. Duncan Moore, PhD Independent Director
Age 66 · As of 4 Mar 2026
Background

Duncan Moore, PhD, has served as a member of our Board of Directors since September 2021. Dr. Moore is a partner at East West Capital Partners since May 2008. Previously, Dr. Moore was a top-ranked pharmaceutical analyst at Morgan Stanley from 1991 to 2008 and was a Managing Director from 1997 to 2008 leading the firm's global healthcare equity research team. Whilst at the University of Cambridge, he co-founded a medical diagnostics company, Ultra Clone, with two colleagues which led to the beginnings of a 20-year career in healthcare capital markets analysis. In 1986, he was involved in establishing the BankInvest biotechnology funds and was on their scientific advisory board. Dr. Moore was educated in Edinburgh and attended the University of Leeds where he studied Biochemistry and Microbiology. He has a M.Phil. and Ph.D. from the University of Cambridge where he was also a post-doctoral research fellow. He served on the board of directors of Forward Pharma A/S until 2025. Currently, he is an active investor in biomedical companies and he has a board position at Cycle Pharma and ASP Isotopes. He is also the Chairman of the Scottish Life Sciences Association and serves on the Board of Governors of Merchiston Castle School in Edinburgh and the International School in Shenzhen in the Peoples Republic of China.

Julie Ryan, F.C.A. Vice President, Finance
Age 40 · As of 4 Mar 2026
Background

Julie Ryan, FCA, has served as our Vice President, Finance since January 2021. Previously, Ms. Ryan has served in a number of senior finance roles including Ardagh Group plc, where she was Group Reporting Manager from 2018 to 2020, Sherry FitzGerald, where she was Commercial Business Partner in 2018, ICON plc, where she was Assistant Manager, Commercial/Finance Business Partnering from 2015 to 2018 and Brambles Ltd, where she was Finance Manager from 2013 to 2015. Ms. Ryan qualified as a chartered accountant with PricewaterhouseCoopers and holds a B.Comm (Acc) from University College Dublin and a MAcc from University College Dublin's Michael Smurfit Graduate Business School.

Florian Schonharting Chairman of the Board
Age 57 · As of 4 Mar 2026
Background

Florian Schonharting, has served as the Chairman of our Board of Directors since 2018. Mr. Schonharting is one of our co-founders. Mr. Schonharting is also co-founder of Forward Pharma A/S, served on its board of directors until 2025 and served as Chairman of its board of directors until 2025. He has also founded or co-founded several other biopharmaceutical companies, including Genmab A/S, Veloxis A/S (f/k/a Life Cycle Pharma A/S), Zealand Pharma A/S and Acadia Pharmaceuticals Inc. Mr. Schonharting has more than 25 years of investment executive experience in public and private equity funds involved in the biopharmaceutical industry.

Dr. Velichka Valcheva, M.D.,M.Sc. Chief Executive Officer
Age 51 · As of 4 Mar 2026
Background

Velichka (Villy) Valcheva, MD, MSc, has served as our Chief Executive Officer since September 2024. Prior to this, Dr. Valcheva served as our Chief Medical Officer since February 2024 and Vice President of Clinical Research and Medical Affairs since August 2023. Dr. Valcheva has more than 20 years of experience in various leadership roles in pharmaceutical and biotech industries. Dr. Valcheva served as VP and Head of Medical Affairs International for Albireo from 2020 until 2023, as well as Medical Lead/Monitor FIH study and clinical development from 2022. Prior to this, Dr. Valcheva served as Global Senior Medical Director Oncology - Hepatocellular Carcinoma for Ipsen from 2018 to 2020. Dr. Valcheva holds a Masters in Pharmaceutical Medicine from Trinity College Dublin, Ireland, as well as a Dr. Med. from University of Medicine - Plovdiv, Bulgaria.

From SEC filings, via Futu. Compensation is total reported pay for the most recent fiscal year on file, not base salary alone.

Sectors & themes

Discussion

No comments yet — be the first to weigh in on GHRS.

Sign in to join the discussion.

Scroll to Top